ストックスクリーナーアプリを入手
3.13
3.69%
-0.12
アフターアワーズ：
3.10
-0.03
-0.96%
前日終値:
$3.25
開ける：
$3.25
24時間の取引高:
2.30M
Relative Volume:
0.64
時価総額：
$871.05M
収益：
-
当期純損益:
$-241.99M
株価収益率:
-3.3337
EPS:
-0.9389
ネットキャッシュフロー:
$-133.64M
1週間 パフォーマンス:
-1.57%
1か月 パフォーマンス:
-10.32%
6か月 パフォーマンス:
-29.35%
1年 パフォーマンス:
-22.91%
1日の値動き範囲:
$3.085
$3.32
1週間の範囲:
$3.03
$3.465
52週間の値動き範囲:
$2.61
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
名前
Sana Biotechnology Inc
セクター
電話
(206) 701-7914
住所
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.13 | 912.80M | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-24 | 開始されました | Wedbush | Outperform |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-03-18 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 開始されました | Jefferies | Buy |
| 2025-01-08 | アップグレード | TD Cowen | Hold → Buy |
| 2024-11-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 開始されました | Rodman & Renshaw | Buy |
| 2024-01-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-08-14 | 開始されました | TD Cowen | Market Perform |
| 2023-05-02 | 開始されました | H.C. Wainwright | Neutral |
| 2021-03-01 | 開始されました | BofA Securities | Buy |
| 2021-03-01 | 開始されました | Goldman | Neutral |
| 2021-03-01 | 開始されました | JP Morgan | Neutral |
| 2021-03-01 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Sana Biotechnology Inc (SANA) 最新ニュース
Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sana Biotechnology Inc (SANA) Valuation: PE, PB & Fair Value Analysis - TradingKey
SANA|Sana Biotechnology Inc|Price:3.285|Chg%:+0.105 - TradingKey
Sana Biotechnology Inc (SANA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Sana Biotechnology Inc (SANA) Institutional Confidence - TradingKey
Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology Inc (SANA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sana Biotechnology, Inc. Revenue Breakdown – NASDAQ:SANA - TradingView
SANA|Sana Biotechnology Inc|Price:3.190|Chg%:-0.020 - TradingKey
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SANA|Sana Biotechnology Inc|Price:3.215|Chg%:+0.095 - TradingKey
Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a 167% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation - Seeking Alpha
Sana Biotechnology (SANA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Sana Biotechnology (SANA) Experiences Modest Decline as Stock Nears Support ZoneGolden Cross - dars.gov.et
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM - Yahoo Finance
Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in FocusTick Index - dars.gov.et
Sana Biotechnology - Nasdaq
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D - The Manila Times
Sana Biotechnology Announces Follow-On Publication in The - GlobeNewswire
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Ko - The National Law Review
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA)Contact Levi & Korsinsky Before May 20, 2025 - The National Law Review
Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value IndexesWhat's Changed - simplywall.st
Sana Biotech heads to EASD with diabetes cell therapy update - Longevity.Technology
Sana Biotechnology (SANA) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar - Moomoo
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
Form 4 Sana Biotechnology Inc For: 7 July By Investing.com - Investing.com Nigeria
Sana Biotechnology (SANA) director Hans Bishop receives 6,297 vested RSU shares - Stock Titan
Sana Biotechnology (SANA) Surges Over 12% as Bulls Test Key ResistanceCombination Correction - dars.gov.et
SANA Should I Buy - Intellectia AI
SANA BIOTECHNOLOGY INC (SANA) Stock Chart - ChartMill
Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative? - Sahm
Sana Biotechnology (SANA) Proxy filing Summary - Quartr
Sana Biotechnology (SANA) Q1 2026 earnings summary - Quartr
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 - The Manila Times
Sana Biotechnology Announces Symposium Presentation at the - GlobeNewswire
Citizens reiterates Sana Biotechnology stock rating on IND filing By Investing.com - Investing.com Canada
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Join Class Action to Recover Losses from Sana Biotechnology, Inc - The National Law Review
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025 - The National Law Review
Enterprise value to EBIT forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Price to earnings forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Price to book forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Sana Biotechnology, Inc. Actuals & Estimates (NASDAQ:SANA) - TradingView
SANA Forecast — Price Target — Prediction for 2027 - TradingView
Sana Biotechnology Inc (SANA) 財務データ
収益
当期純利益
現金流量
EPS
Sana Biotechnology Inc (SANA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):